Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Biotechnology
Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was trading 83% lower at midday on Thursday. 25 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab mafodotin in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for multiple myeloma patients who have received at least one prior line of therapy. 25 November 2024
All news
Biotechnology
Last month’s licensing deal by Biogen with Sage Therapeutics to jointly develop and commercialize zuranolone (SAGE-217) and SAGE-324 did not immediately please the latter’s investors, despite being worth a potential $3 billion. 4 December 2020
Biotechnology
Research from industry analyst GlobalData finds that the market for regenerative medicines will expand in the coming years to reach $16.4 billion in annual revenues. 3 December 2020
Biotechnology
The bladder cancer therapeutics market was valued at $670 million in 2018 across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK and Japan) and is expected to grow exponentially at a compound annual growth rate (CAGR) of 23.6% - accruing slightly less than $5.6 billion in 2028. 3 December 2020
Biotechnology
Janssen Pharmaceuticals, a Johnson & Johnson company, has acquired rights to Hemera Biosciences' investigational gene therapy HMR59, administered as a one-time, outpatient, intravitreal injection to help preserve vision in patients with geographic atrophy, a late-stage and severe form of age-related macular degeneration (AMD). 3 December 2020
Biotechnology
Genomics-based drug discovery company Exelixis has exercised its exclusive option for Iconic Therapeutics’ lead oncology antibody-drug conjugate (ADC) program under a May 2019 agreement that also involves Zymeworks. 2 December 2020
Biotechnology
British contract development and manufacturing organization (CDMO) Sterling Pharma Solutions has announced a new strategic partnership with ADC Biotechnology (ADC Bio), a UK based biotechnology company specializing in antibody drug conjugates. 2 December 2020
Biotechnology
US biopharma Global Blood Therapeutics has announced the initiation of an early access program for voxelotor in Europe and other regions outside the USA, for the treatment of hemolytic anemia in sickle cell disease (SCD) patients aged 12 years and older. 2 December 2020
Biotechnology
Tapping into a wave of innovation, Germany's Bayer is to launch a dedicated unit to bolster its internal cell and gene therapy capabilities. 2 December 2020
Biotechnology
European and American regulatory submissions for Agios Pharmaceuticals’ mitapivat are imminent, following positive results from the Phase III ACTIVATE trial. 2 December 2020
Biotechnology
The first COVID-19 vaccine for the UK, developed by Pfizer and Germany’s BioNTech, has today been given approval for use following a thorough review carried out by the Medicines and Healthcare products Regulatory Agency (MHRA). 2 December 2020
Biotechnology
Shares of USA-based Moleculin Biotech shot up more than 33% to $1.04 yesterday, after in revealed that the US Food and Drug Administration has approved its request for a Rare Pediatric Disease (RPD) designation for its drug candidate WP1066. 2 December 2020
Biotechnology
The US regulator has granted approval for Roche to market Xolair (omalizumab) for the add-on maintenance treatment of nasal polyps in adults. 2 December 2020
Biotechnology
The US Food and Drug Administration yesterday approved Blueprint Medicines’ Gavreto (pralsetinib) for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC). 2 December 2020
Biotechnology
California’s BridgeBio Pharma has announced that its affiliate QED Therapeutics has had its New Drug Application (NDA) accepted by the US Food and Drug Administration (FDA) for infigratinib, an oral FGFR1-3 selective inhibitor, for cholangiocarcinoma. 1 December 2020
Biotechnology
MaaT Pharma has secured an additional 7.35 million euros ($8.7 million) in an extension of its Series B financing, bringing the total raised in this round to 25.35 million euros. 1 December 2020
Biotechnology
Biotech firm Zymeworks today announced that its partner, China’s BeiGene, has dosed the first patient in South Korea in a pivotal, single-arm clinical trial of Cmonotherapy in patients with advanced or metastatic HER2-amplified biliary tract cancer (BTC). 1 December 2020
Biotechnology
Boosting its position as the leading developer of oral CGRP-receptor blockers, Biohaven Pharmaceutical has entered into a global collaboration and license deal with Japan’s Sosei Group. 1 December 2020
Biotechnology
US healthcare giant Johnson & Johnson’s subsidiary Janssen says that the European Commission has granted marketing authorization for Tremfya (guselkumab), alone or in combination with methotrexate (MTX), for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy. 1 December 2020
Biotechnology
Privately-held Scottish biotech ILC Therapeutics has secured an investment from Medical Incubator Japan, a Tokyo-based fund specializing in healthcare. 1 December 2020
Biotechnology
Canadian biotech Zymeworks today revealed that the US Food and Drug Administration has granted Breakthrough Therapy designation for zanidatamab (formerly known as ZW25) in patients with previously-treated HER2 gene-amplified biliary tract cancer (BTC). 30 November 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze